Evidence map›Paper›PMID 31020708›Full record

ArticleMolecular carcinogenesis2019

Pleotropic role of RNA binding protein CELF2 in autophagy induction.

Jacob New, Dharmalingam Subramaniam, Satish Ramalingam, Jonathan Enders, Afreen Asif Ali Sayed, Sivapriya Ponnurangam, David Standing, Prabhu Ramamoorthy, Maura O'Neil, Dan A Dixon and 6 more

Open access · greenAbstract read
In one paragraph

Article in Molecular carcinogenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Role of CELF2 in ferroptosis: Potential targets for cancer therapy (Review).International journal of molecular medicine · 2023
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Jacob NewDepartment of Anatomy & Cell Biology, University of Kansas Medical Center, Kansas, Kansas.
Dharmalingam SubramaniamDepartment of Cancer Biology, University of Kansas Medical Center, Kansas, Kansas.
Satish RamalingamDepartment of Cancer Biology, University of Kansas Medical Center, Kansas, Kansas.
Jonathan EndersDepartment of Anatomy & Cell Biology, University of Kansas Medical Center, Kansas, Kansas.
Afreen Asif Ali SayedDepartment of Cancer Biology, University of Kansas Medical Center, Kansas, Kansas.
Sivapriya PonnurangamDepartment of Cancer Biology, University of Kansas Medical Center, Kansas, Kansas.
David StandingDepartment of Cancer Biology, University of Kansas Medical Center, Kansas, Kansas.
Prabhu RamamoorthyDepartment of Cancer Biology, University of Kansas Medical Center, Kansas, Kansas.
Maura O'NeilDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas, Kansas.
Dan A DixonDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas.
Subhrajit SahaDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas, Kansas.
Shahid UmarDepartment of General Surgery, University of Kansas Medical Center, Kansas, Kansas.
Sumedha GunewardenaDepartment of Molecular Integrative Physiology, University of Kansas Medical Center, Kansas, Kansas.
Roy A JensenDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas, Kansas.
Sufi Mary ThomasDepartment of Anatomy & Cell Biology, University of Kansas Medical Center, Kansas, Kansas.ORCID 0000-0001-5370-0842
Shrikant AnantDepartment of Cancer Biology, University of Kansas Medical Center, Kansas, Kansas.
The University of Kansas Cancer Center · USUniversity of Kansas Medical Center · USUniversity of Kansas · US

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Using PCORnet to Expand the DS-CONNECT Cohort Through Healthcare System Recruitment, Incorporating Electronic Health Records, and Assessing Self-DeterminationU54HD090216 · NICHD · UNIVERSITY OF KANSAS LAWRENCE · PI COLOMBO, JOHN A. · 2016 to 2020
$6.2M
Progenitor cell based therapy to mitigate radiation induced gastro intestinal syndrome- supplementU01AI138323 · NIAID · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SAHA, SUBHRAJIT · 2018 to 2022
$2.8M
Bitter Melon Component and Colon Cancer PreventionR01CA190291 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ANANT, SHRIKANT, UMAR, SHAHID · 2014 to 2018
$2.7M
Novel Dual Notch/PXR Targeting for Colon Cancer TherapyR01CA182872 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ANANT, SHRIKANT, WEIR, SCOTT JAMES · 2014 to 2018
$2.6M
Role of autophagy in the tumor microenvironmentR01CA227838 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI THOMAS, SUFI MARY · 2019 to 2023
$1.9M
NCI NIH HHS P30 CA168524NCI NIH HHS R01 CA182872NCI NIH HHS R01 CA190291NCI NIH HHS R01 CA227838NIAID NIH HHS U01 AI138323NICHD NIH HHS U54 HD090216
6 · The paper itself

Abstract

We previously reported that ionizing radiation (IR) mediates cell death through the induction of CUGBP elav-like family member 2 (CELF2), a tumor suppressor. CELF2 is an RNA binding protein that modulates mRNA stability and translation. Since IR induces autophagy, we hypothesized that CELF2 regulates autophagy-mediated colorectal cancer (CRC) cell death. For clinical relevance, we determined CELF2 levels in The Cancer Genome Atlas (TCGA). Role of CELF2 in radiation response was carried out in CRC cell lines by immunoblotting, immunofluorescence, autophagic vacuole analyses, RNA stability assay, quantitative polymerase chain reaction and electron microscopy. In vivo studies were performed in a xenograft tumor model. TCGA analyses demonstrated that compared to normal tissue, CELF2 is expressed at significantly lower levels in CRC, and is associated with better overall 5-year survival in patients receiving radiation. Mechanistically, CELF2 increased levels of critical components of the autophagy cascade including Beclin-1, ATG5, and ATG12 by modulating mRNA stability. CELF2 also increased autophagic flux in CRC. IR significantly induced autophagy in CRC which correlates with increased levels of CELF2 and autophagy associated proteins. Silencing CELF2 with siRNA, mitigated IR induced autophagy. Moreover, knockdown of CELF2 in vivo conferred tumor resistance to IR. These studies elucidate an unrecognized role for CELF2 in inducing autophagy and potentiating the effects of radiotherapy in CRC.

Indexed as

AnimalsAutophagyAutophagy-Related Protein 12Autophagy-Related Protein 5Beclin-1CELF ProteinsCell Line, TumorCell SurvivalColorectal NeoplasmsHCT116 CellsHumansMaleMiceNeoplasm TransplantationNerve Tissue ProteinsPrognosisATG12 protein, humanATG5 protein, humanAutophagy-Related Protein 12Autophagy-Related Protein 5Beclin-1BECN1 protein, humanCELF2 protein, humanCELF ProteinsNerve Tissue ProteinsRNA, MessengerRNA, Small Interferingautophagycolorectal cancerradiotherapyRNA binding protein

Identifiers

PMID31020708
PMCPMC6602857
OpenAlexW2941850173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.